Five Steps to Guide Suc­cess­ful Risk-Based De­cen­tral­ized Clin­i­cal Tri­als

Last week

Open & Flex­i­ble Tech­nol­o­gy Can En­able Break­through In­no­va­tion

3 weeks ago

The In­ge­nu­ity En­gine: Trans­la­tion­al Re­search and the Need for Speed

4 weeks ago

FSP and COVID-19: Im­pact on Clin­i­cal Tri­al De­vel­op­ment

Last month

Cell and Gene Con­tract Man­u­fac­tur­ers Must Em­brace Dig­i­ti­za­tion

Last month

Aus­tralia, home to a world-class ear­ly phase clin­i­cal tri­al ecosys­tem

2 months ago

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

2 months ago

$48 Bil­lion Is Lost to Avoid­able Ex­per­i­ment Ex­pen­di­ture Every Year

3 months ago

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

3 months ago

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

3 months ago

De­cen­tral­ized Clin­i­cal Tri­als: The fu­ture of clin­i­cal tri­als is now

4 months ago

A Fast Way to Curb Drug De­vel­op­ment Costs? Make Fail­ure a Strat­e­gy.

4 months ago

Tak­ing Ac­tion to En­sure Clin­i­cal Tri­al Progress Dur­ing COVID-19

4 months ago

Five strate­gies for mit­i­gat­ing the im­pact of COVID-19 on clin­i­cal tri­als

4 months ago

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

6 months ago

Ad­dress­ing Key Chal­lenges of Lipid-Me­di­at­ed De­liv­ery Sys­tems for mR­NA through In­no­va­tion

6 months ago

Zhi­meng Bio­phar­ma An­nounces the First-in-Hu­man Dos­ing in Phase I Clin­i­cal Tri­al of ZM-H1505R De­signed for the Treat­ment of Chron­ic He­pati­tis B Virus In­fec­tion

6 months ago

Lessons for biotech and phar­ma from a doc­tor who chased his own cure

7 months ago

A New Fron­tier: The In­ner Ear

7 months ago

2019 Trin­i­ty Drug In­dex Eval­u­ates Ac­tu­al Com­mer­cial Per­for­mance of Nov­el Drugs Ap­proved in 2016

8 months ago

How to cap­i­talise on a lean launch

8 months ago

Turn­ing the cor­ner on treat­ing the root cause of sick­le cell dis­ease

8 months ago

Es­sen­tial cri­te­ria bio­phar­ma­ceu­ti­cal in­vestors seek when eval­u­at­ing com­pounds and com­pa­nies

8 months ago

In­vent­ing Med­i­cine by Ac­cess­ing the Hid­den Trea­sure in the Hu­man Mi­cro­bio­me’s Dark Mat­ter

8 months ago
123 Next page Last page